Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03028103
Title Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Epizyme, Inc.
Indications

B-cell lymphoma

diffuse large B-cell lymphoma

mantle cell lymphoma

Therapies

Fluconazole + Tazemetostat

Omeprazole + Repaglinide + Tazemetostat

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Arizona Cancer Center Tucson Arizona 85719 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
Columbia University Medical Center New York New York 10032 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field